REGULATORY CONSIDERATIONS ON ADDITIONAL RISK MINIMIZATION MEASURES IN EUROPE
DOI:
https://doi.org/10.22159/ajpcr.2025v18i5.54374Keywords:
Additional risk minimization measures, Risk management plan, Risk minimization strategy, Monitoring and ReportingAbstract
Additional Risk Minimization Measures (aRMMs) are crucial in the European regulatory framework to enhance pharmaceutical safety when routine risk management strategies are inadequate. These measures are implemented when a medicinal product poses risks such as severe adverse reactions, misuse, or teratogenicity, which cannot be adequately controlled through standard pharmacovigilance processes. In Europe, the European Medicines Agency (EMA) plays a central role in overseeing the development, implementation, and monitoring of aRMMs, ensuring that these strategies are both effective and compliant with EU pharmacovigilance legislation. While prior reviews have examined pharmacovigilance strategies, gaps remain in assessing the real-world implementation challenges of aRMMs, their regulatory effectiveness, and their impact on healthcare systems and patient access. Current regulatory reviews have not comprehensively addressed the evolving complexities of compliance with EU pharmacovigilance legislation, particularly in balancing stringent safety requirements with practical drug accessibility. This review bridges these gaps by analyzing the regulatory framework governing aRMMs, including legal mandates for risk management plans (RMPs), post-marketing surveillance strategies, and ongoing safety monitoring through registries and studies. By offering a novel perspective on optimizing aRMM implementation and identifying areas for regulatory enhancement, this review contributes to a more comprehensive understanding of risk minimization strategies. It stresses the necessity for continuous evaluation and adaptation to ensure that pharmaceutical benefits outweigh risks while maintaining accessibility.
Downloads
References
Hines PA, Gonzalez-Quevedo R, Lambert AI, Janssens R, Freischem B, Torren Edo J, et al. Regulatory science to 2025: An analysis of stakeholder responses to the European medicines agency’s strategy. Front Med (Lausanne). 2020 Sep 23;7:508. doi: 10.3389/ fmed.2020.00508, PMID: 33072771
Bolcato M, Russo M, Trentino K, Isbister J, Rodriguez D, Aprile A. Patient blood management: The best approach to transfusion medicine risk management. Transfus Apher Sci. 2020 Aug 1;59(4):102779. doi: 10.1016/j.transci.2020.102779, PMID: 32359972
Kulkarni GP, Patil LV. Analysis of adverse drug reactions spontaneously reported to adverse drug monitoring centre of a tertiary care Hospital prospective study. Int J Curr Pharm Res. 2018;10(1):23-5. doi: 10.22159/ ijcpr.2018v10i1.24403
Goedecke T, Martirosyan L, Gault N, Seifert K, Morales DR, Bahri P, et al. Studying the impact of European union regulatory interventions for minimising risks from medicines: Lessons learnt and recommendations. Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5874. doi: 10.1002/ pds.5874, PMID: 39092454
Gonzalez‐Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, et al. The path to a better biomarker: Application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice. J Pathol. 2020 Apr;250(5):667-84. doi: 10.1002/path.5406, PMID: 32129476
Sankeshwari S, Gangadharappa HV, Asha Spandana KM, Eliyas A, Thirumaleshwar S, Harsha Vardhan PV. A review on the solid oral dosage form for pediatrics, regulatory aspects, challenges involved during the formulation, and toxicity of the excipients used in pediatric formulation. Int J Appl Pharm. 2023;15(3):12-27. doi: 10.22159/ijap.2023v15i3.47313
Kataria BC, Mehta D, Chhaiya SB. Approval of new nervous system drugs in India compared with the us and eu. Int J Pharm Pharm Sci. 2012;4(4):706-9.
Zhang M, Marklund H, Dhawan N, Gupta A, Levine S, Finn C. Adaptive risk minimization: Learning to adapt to domain shift. Adv Neural Inf Process Syst. 2021 Dec 6;34:23664-78.
Hugman B, Skalli S. Pharmacovigilance and risk communication for the safe use of herbal and traditional medicines: How to promote evidence and keep people safe. In: Barnes J, editor. Pharmacovigilance for Herbal and Traditional Medicines: Advances, Challenges and International Perspectives. Cham: Springer International Publishing; 2022 Aug 12. p. 261-76. doi: 10.1007/978-3-031-07275-8-15
Benami E, Jin Z, Carter MR, Ghosh A, Hijmans RJ, Hobbs A, et al. Uniting remote sensing, crop modelling and economics for agricultural risk management. Nat Rev Earth Environ. 2021 Feb;2(2):140-59. doi: 10.1038/s43017-020-00122-y
Kumar RD. The phases of clinical trials: From preclinical studies to post-market surveillance. Glob J Med Clin Case Rep. 2024 Dec 26;11:55- 65. doi: 10.17352/2455-5282.000189
Altıntaş Aykan D, Ergün Y. Isotretinoin: Still the cause of anxiety for teratogenicity. Dermatol Ther. 2020 Jan;33(1):e13192. doi: 10.1111/ dth.13192, PMID: 31837244
Zhang H, Hua D, Huang C, Samal SK, Xiong R, Sauvage F, et al. Materials and technologies to combat counterfeiting of pharmaceuticals: Current and future problem tackling. Adv Mater. 2020 Mar;32(11):e1905486. doi: 10.1002/adma.201905486, PMID: 32009266
Tomasone JR, Kauffeldt KD, Chaudhary R, Brouwers MC. Effectiveness of guideline dissemination and implementation strategies on health care professionals’ behaviour and patient outcomes in the cancer care context: A systematic review. Implement Sci. 2020 Dec;15(1):41. doi: 10.1186/s13012-020-0971-6, PMID: 32493348
Dernoncourt A, Liabeuf S, Bennis Y, Masmoudi K, Bodeau S, Laville S, et al. Fetal and neonatal adverse drug reactions associated with biologics taken during pregnancy by women with autoimmune diseases: Insights from an analysis of the world health organization pharmacovigilance database (VigiBase®). BioDrugs. 2023 Jan;37(1):73-87. doi: 10.1007/ s40259-022-00564-4, PMID: 36401769
Rašković A, Steinbach M, Mugoša S, Baljak J, Prodanović D, Sabo S, et al. Patient information leaflets: How do patients comprehend and understand drug information? Arch Pharm Pract. 2024;15(1)(1- 2024):7-11. doi: 10.51847/n2jlaSAlbK
Chapman MJ, Zamorano JL, Parhofer KG. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid. Pharmacol Ther. 2022 Sep 1;237:108172. doi: 10.1016/j. pharmthera.2022.108172, PMID: 35304222
Renn O. Risk communication: Insights and requirements for designing successful communication programs on health and environmental hazards. In: Heath RL, O’Hair HD, editors. Handbook of Risk andCrisis Communication. United Kingdom: Routledge; 2020 Oct 28. p. 80-98. doi: 10.4324/9781003070726-5
Pore AV, Bais SK, Kamble MM. Pharmacovigilance in clinical research. Int J Pharm Herb Technol. 2024;2(1):759-75.
Butler D, Vucic K, Straus S, Cupelli A, Micallef B, Serracino-Inglott A, et al. Regulatory experience of handling risk management plans (RMPs) for medicinal products in the EU. Expert Opin Drug Saf. 2021 Jul 3;20(7):815-26. doi: 10.1080/14740338.2021.1909569, PMID: 33843379
Chatzopoulou S, Eriksson NL, Eriksson D. Improving risk assessment in the European food safety authority: Lessons from the European medicines agency. Front Plant Sci. 2020 Apr 6;11:349. doi: 10.3389/ fpls.2020.00349, PMID: 32318080
Heng H, Jazayeri D, Shaw L, Kiegaldie D, Hill AM, Morris ME. Hospital falls prevention with patient education: A scoping review. BMC Geriatr. 2020 Dec;20(1):140. doi: 10.1186/s12877-020-01515-w, PMID: 32293298
Staub C, Fuchs C, Siegrist M. Risk perception and acceptance of health warning labels on wine. Food Qual Prefer. 2022 Mar 1;96:104435. doi: 10.1016/j.foodqual.2021.104435
Bruinen De Bruin Y, Lequarre AS, McCourt J, Clevestig P, Pigazzani F, Zare Jeddi M, et al. Initial impacts of global risk mitigation measures taken during the combatting of the COVID-19 pandemic. Saf Sci. 2020 Aug 1;128:104773. doi: 10.1016/j.ssci.2020.104773, PMID: 32296266
Goswami S, Eckert L, Sturgill M, Ramos R, Bridgeman MB. Patient education on self-administration of insulin via pen: An interprofessional team-based educational initiative. J Interprof Educ Pract. 2023 Sep 1;32:100663. doi: 10.1016/j.xjep.2023.100663
Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: Strategies to address key barriers within the treatment system. NAM Perspect. 2020 Apr 27;2020:10-31478. doi: 10.31478/202004b, PMID: 35291732
Paczkowska A, Hoffmann K, Kus K, Kopciuch D, Zaprutko T, Ratajczak P, et al. Impact of patient knowledge on hypertension treatment adherence and efficacy: A single-centre study in Poland. Int J Med Sci. 2021 Jan 1;18(3):852-60. doi: 10.7150/ijms.48139, PMID: 33437222
Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, et al. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: Challenges and opportunities. Nat Rev Neurol. 2020 Jul 15;16(7):381-400. doi: 10.1038/s41582-020- 0362-2, PMID: 32541893
Battino D, Tomson T, Bonizzoni E, Craig J, Perucca E, Sabers A, et al. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol. 2024 May 1;81(5):481-9. doi: 10.1001/jamaneurol.2024.0258, PMID: 38497990
McGrath SP, McGovern KM, Perreard IM, Huang V, Moss LB, Blike GT. Inpatient respiratory arrest associated with sedative and analgesic medications: Impact of continuous monitoring on patient mortality and severe morbidity. J Patient Saf. 2021 Dec 1;17(8):557- 61. doi: 10.1097/PTS.0000000000000696, PMID: 32175965
Gaudio M, Konstantara E, Joy M, Van Vlymen J, De Lusignan S. Valproate prescription to women of childbearing age in English primary care: Repeated cross-sectional analyses and retrospective cohort study. BMC Pregnancy Childbirth. 2022 Jan 27;22(1):73. doi: 10.1186/ s12884-021-04351-x, PMID: 35086478
National Research Council, Division on Earth, Life Studies, Board on Environmental Studies. Committee to Review the IRIS Process. Review of EPA’s Integrated Risk Information System (IRIS) Process. United States: National Academies Press; 2014.
Fraser AG, Byrne RA, Kautzner J, Butchart EG, Szymański P, Leggeri I, et al. Implementing the new European regulations on medical devices-clinical responsibilities for evidence-based practice: A report from the regulatory affairs committee of the European society of cardiology. Eur Heart J. 2020 Jul 14;41(27):2589-96. doi: 10.1093/eurheartj/ehaa382, PMID: 32484542
De Caux D, Mariappa G, Perera G, Girling J. Prescribing for pregnancy: Chronic skin diseases. Drug Ther Bull. 2023 Apr 1;61(4):55-60. doi: 10.1136/dtb.2022.000036, PMID: 36990470
Heyward J, Olson L, Sharfstein JM, Stuart EA, Lurie P, Alexander GC. Evaluation of the extended-release/long-acting opioid prescribing risk evaluation and mitigation strategy program by the US food and drug administration: A review. JAMA Intern Med. 2020 Feb 1;180(2):301-9. doi: 10.1001/jamainternmed.2019.5459, PMID: 31886822
Reinold J, Kollhorst B, Wentzell N, Platzbecker K, Haug U. Use of isotretinoin among girls and women of childbearing age and occurrence of isotretinoin-exposed pregnancies in Germany: A population-based study. PLoS Med. 2024 Jan 25;21(1):e1004339. doi: 10.1371/journal. pmed.1004339, PMID: 38271295
Shenfadu DR. Synthesis and biological study of pyrazoles, amino-pyrimidines and malononitriles derived from cyclic imides. Int J Chem Res. 2012;2016;March:3 312.
Klatte K, Pauli-Magnus C, Love SB, Sydes MR, Benkert P, Bruni N, et al. Monitoring strategies for clinical intervention studies. Cochrane Database Syst Rev. 2021;12(12):MR000051. doi: 10.1002/14651858. MR000051.pub2, PMID: 34878168
Ivask M, Kurvits K, Uusküla M, Juppo A, Laius O, Siven M. Compliance with pregnancy prevention recommendations for isotretinoin following the amendment of the European union pregnancy prevention program: A repeat study in Estonia. Drugs Real World Outcomes. 2024 Mar;11(1):91-8. doi: 10.1007/s40801-023-00381-3, PMID: 37462893
Shroukh WA. Risk Management of Thalidomide in Jordan: An Application of the World Health Organization’s Health Systems Framework. UK: University Manchester; 2020.
Dhara S, Moore EE, Yaffe MB, Moore HB, Barrett CD. Modern management of bleeding, clotting, and coagulopathy in trauma patients: What is the role of viscoelastic assays? Curr Trauma Rep. 2020 Mar;6(1):69-81. doi: 10.1007/s40719-020-00183-w, PMID: 32864298
Marcucci R, Berteotti M, Gragnano F, Galli M, Cavallari I, Renda G, et al. Monitoring antiplatelet therapy: Where are we now? J Cardiovasc Med (Hagerstown). 2023 Apr 1;24(Suppl 1):e24-35. doi: 10.2459/ JCM.0000000000001406, PMID: 36729588
Allocati E, Bertele’ V, Gerardi C, Garattini S, Banzi R. Clinical evidence supporting the marketing authorization of biosimilars in Europe. Eur J Clin Pharmacol. 2020 Apr;76(4):557-66. doi: 10.1007/s00228-019- 02805-y, PMID: 31897530
Oberweis CV, Marchal JA, López-Ruiz E, Gálvez-Martín P. A worldwide overview of regulatory frameworks for tissue-based products. Tissue Eng Part B Rev. 2020 Apr 1;26(2):181-96. doi: 10.1089/ten.TEB.2019.0315, PMID: 31910099
Treacy J, Morrato EH, Horne R, Wolf MS, Bakhai A, Wilson MC, et al. Behavioral science: Enhancing our approach to the development of effective additional risk minimization strategies. Drug Saf. 2024 Aug;47(8):733-43. doi: 10.1007/s40264-024-01420-w, PMID: 38594553
Lewis DJ, McCallum JF. Utilizing advanced technologies to augment pharmacovigilance systems: Challenges and opportunities. Ther Innov Regul Sci. 2020 Jul;54(4):888-99. doi: 10.1007/s43441-019-00023-3, PMID: 32557311
Hughes JE, Buckley N, Looney Y, Kirwan G, Mullooly M, Bennett KE. Evaluating awareness, knowledge and practice of healthcare professionals following implementation of a revised pregnancy prevention programme for isotretinoin in Ireland: A multi‐stakeholder cross‐sectional study. Pharmacoepidemiol Drug Saf. 2023 Feb;32(2):137-47. doi: 10.1002/pds.5538, PMID: 36073295
Kramer DB, Xu S, Kesselheim AS. Regulation of medical devices in the United States and European Union. The Ethical Challenges of Emerging Medical Technologies. United Kingdom: Routledge; 2020 Sep 10. p. 41-8. doi: 10.4324/9781003074984-3
Albassam A, Hughes DA. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics. Eur J Clin Pharmacol. 2021 Feb;77(2):251-60. doi: 10.1007/s00228-020-03003-x, PMID: 32989529
Essink SC, Zomerdijk IM, Straus SM, Gardarsdottir H, De Bruin ML. Duration of effectiveness evaluation of additional risk minimisation measures for centrally authorised medicinal products in the EU between 2012 and 2021. Drug Saf. 2023 Oct;46(10):1007-20. doi: 10.1007/ s40264-023-01341-0, PMID: 37658281
Sedrakyan A, Marinac-Dabic D, Campbell B, Aryal S, Baird CE, Goodney P, et al. Advancing the real-world evidence for medical devices through coordinated registry networks. BMJ Surg Interv Health Technol. 2022 Nov 11;4(Suppl 1):e000123. doi: 10.1136/ bmjsit-2021-000123, PMID: 36393894
Xie X, Song Q, Dai C, Cui S, Tang R, Li S, et al. Clinical safety and efficacy of allogenic human adipose mesenchymal stromal cells-derived exosomes in patients with mild to moderate Alzheimer’s disease: A phase I/II clinical trial. Gen Psychiatr. 2023 Oct 11;36(5):e101143. doi: 10.1136/gpsych-2023-101143, PMID: 37859748
Holm JE, Ruppert JG, Ramsden SD. Impact of changing regulations and the dynamic nature of European risk management plans for human medicines on the lifecycle of safety concerns. PharmaceutMed. 2022 Feb;36(1):33-46. doi: 10.1007/s40290-021-00414-8, PMID: 35099785
Trifirò G, Crisafulli S. A new era of pharmacovigilance: Future challenges and opportunities. Front Drug Saf Regul. 2022 Feb 25;2:866898. doi: 10.3389/fdsfr.2022.866898
Peters T, Soanes N, Abbas M, Ahmad J, Delumeau JC, Herrero- Martinez E, et al. Effective pharmacovigilance system development: EFPIA-IPVG consensus recommendations. Drug Saf. 2021 Jan;44(1):17-28. doi: 10.1007/s40264-020-01008-0, PMID: 33289904
Sharma R, Kant K, Kumar A. Overview of periodic safety update reports: Where have we reached? Appl Clin Res Clin Trials Regul Aff. 2020 Apr 1;7(1):4-11. doi: 10.2174/2213476X06666190823151514
Alharbi AB, Berrou I, Umaru N, Al Hamid A, Shebl NA. Factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: A systematic review. Res Social Adm Pharm. 2023 Jan 1;19(1):28-56. doi: 10.1016/j. sapharm.2022.07.003, PMID: 35989221
Kürzinger ML, Douarin L, Uzun I, El-Haddad C, Hurst W, Juhaeri J, et al. Structured benefit-risk evaluation for medicinal products: Review of quantitative benefit-risk assessment findings in the literature. Ther Adv Drug Saf. 2020 Dec;11:1-12. doi: 10.1177/2042098620976951, PMID: 33343857
Hoeve CE, Francisca RD, Zomerdijk I, Sturkenboom MC, Straus SM. Description of the risk management of medication errors for centrally authorised products in the European Union. Drug Saf. 2020 Jan;43(1):45- 55. doi: 10.1007/s40264-019-00874-7, PMID: 31617081
Fichtenberg C, Delva J, Minyard K, Gottlieb LM. Health and human services integration: Generating sustained health and equity improvements. Health Aff (Millwood). 2020 Apr 1;39(4):567- 73. doi: 10.1377/hlthaff.2019.01594, PMID: 32250685
Flynn R, Hedenmalm K, Murray‐Thomas T, Pacurariu A, Arlett P, Shepherd H, et al. Ability of primary care health databases to assess medicinal products discussed by the European Union pharmacovigilance risk assessment committee. Clin Pharmacol Ther. 2020 Apr;107(4):957- 65. doi: 10.1002/cpt.1775, PMID: 31955404
Shi J, Chen X, Hu H, Ung CO. Application of implementation science framework to develop and adopt regulatory science in different national regulatory authorities. Front Public Health. 2023 May 4;11:1172557. doi: 10.3389/fpubh.2023.1172557, PMID: 37213606
Janssen M, Brous P, Estevez E, Barbosa L, Janowski T. Data governance: Organizing data for trustworthy artificial intelligence. Gov Inf Q. 2020 Jul 1;37(3):101493. doi: 10.1016/j.giq.2020.101493
Wright JS, Doukas D. Challenges to sovereign ambitions: Forces of convergence and divergence within the global pharmaceutical sector and the UK’s withdrawal from the European Union. Health Econ Policy Law. 2021 Jul;16(3):256-72. doi: 10.1017/S174413312000016X, PMID: 32583755
Rimkutė D, Mazepus H. A widening authority-legitimacy gap in EU regulatory governance? An experimental study of the European medicines agency’s legitimacy in health security regulation. J Eur Public Policy. 2023 Jul 3;30(7):1406-30. doi: 10.1080/13501763.2023.2171091
Bhasale AL, Sarpatwari A, De Bruin ML, Lexchin J, Lopert R, Bahri P, et al. Postmarket safety communication for protection of public health: A comparison of regulatory policy in Australia, Canada, the European Union, and the United States. Clin Pharmacol Ther. 2021 Jun;109(6):1424-42. doi: 10.1002/cpt.2010, PMID: 32767557
Muehlematter UJ, Daniore P, Vokinger KN. Approval of artificial intelligence and machine learning-based medical devices in the USA and Europe (2015-20): A comparative analysis. Lancet Digit Health. 2021 Mar 1;3(3):e195-203. doi: 10.1016/S2589-7500(20)30292-2, PMID: 33478929
Ponnapalli R, Divya MS, Raju KV, Nori LP. Regulatory framework: Vaccine development in us, India and eu. Int J Appl Pharm. 2023;15(2):63-71. doi: 10.22159/ijap.2023v15i2.46723
Gnanasakthy A, Levy C, Norcross L, Doward L, Winnette R. A review of labeling based on patient-reported outcome endpoints for new oncology drugs approved by the European medicines agency (2017-2021). Value Health. 2023 Jun 1;26(6):893-901. doi: 10.1016/j.jval.2023.01.017, PMID: 36746305
Grupstra RJ, Goedecke T, Scheffers J, Strassmann V, Gardarsdottir H. Review of studies evaluating effectiveness of risk minimization measures assessed by the European medicines agency between 2016 and 2021. Clin Pharmacol Ther. 2023 Dec;114(6):1285-92. doi: 10.1002/ cpt.3034, PMID: 37634124
Singh S, Sharma MP, Misra G. Regulatory bodies. In: Quality Control and Regulatory Aspects for Biologicals. United States: CRC Press; 2024 Apr 22. p. 137-59. doi: 10.1201/9781032697444-9
Published
How to Cite
Issue
Section
Copyright (c) 2025 Mr. John Giridharan IVR, Dr. R. Srinivasan
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
